“svb-leerink” Archives

in
Entry Author Date Location
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects 10/15/20 Boston
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma 10/13/20 San Diego
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats 10/09/20 Europe
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug 10/08/20 National
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries 10/01/20 Europe
Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 09/23/20 Europe
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug 09/16/20 Wisconsin
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More 09/11/20 National
Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test 09/10/20 San Francisco
AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase 09/04/20 National
Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout 08/26/20 San Diego
MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T 08/03/20 Europe
Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test 07/28/20 New York
Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test 07/15/20 Boston
Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder 06/30/20 San Francisco
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug 06/05/20 New York
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact 05/27/20 San Francisco
Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola 05/05/20 Boston
FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer 04/20/20 National
GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year 04/14/20 National
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy 03/31/20 Raleigh Durham
Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data 03/10/20 Boston
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come 02/10/20 New York
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
CEOs of Women’s Health Companies Fight to Open Investment Floodgates 01/22/20 San Diego
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug 01/13/20 National
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
Apellis Rare Blood Disease Drug Tops Alexion’s in Head-to-Head Test 01/07/20 Boston
Page 1 of 2 next page »